Results 41 to 50 of about 5,279 (205)
, 2022 The overall goals of this query are to 1) characterize the growth in patients receiving Paxlovid over time and 2) examine Paxlovid use by patient characteristics, including by acute SARS CoV-2 infection profile and healthcare utilization. Patients with a COVID index date or a visit date between 12/1/2021 (7 days before EUA) and 5/30/2022 are included ...
openaire +1 more source
Angewandte Chemie, Volume 138, Issue 40, 28 September 2026.Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee +5 more
wiley +2 more sources
Journal of Infection and Public HealthBackground: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19?
María Elena Camacho Moll +6 more
doaj +1 more source
Ondansetron in a Paxlovid Intolerant Man
Austin Journal of Clinical Case Reports, 2022 A symptomatic 22-year-old man, unvaccinated and living with high-risk elder parents, was prescribed nirmatrelvir/ritonavir (Paxlovid®) after testing positive for COVID-19. The patient developed persistent moderate to severe nausea after the first dose, progressing to severe nausea and several vomiting episodes after the second dose.
LG, Cubeddu, TM, Dalley, LX, Cubeddu
openaire +1 more source
Infectious Diseases and Therapy, 2023 Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective therapeutic interventions are urgently required. We clarified the safety and efficacy of Paxlovid in the treatment of elderly patients with coronavirus disease ...
Chengzhao Weng +8 more
doaj +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 CHUUKESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
opensafely/Paxlovid-and-sotrovimab
, 2023 Clinical codelists, Stata DO files, and Python code for effectiveness and safety of Paxlovid and sotrovimab for prevention of severe COVID-19 outcomes.
lshbz1, Zheng, Bang
core +3 more sources
A real‐world analysis of AI chatbot performance for medicines information enquiries
Journal of Pharmacy Practice and Research, EarlyView.Abstract Background The provision of medicines information (MI) services requires interpretation and clinical judgement of complex scenarios by pharmacists. To date, few studies have assessed the performance of artificial intelligence (AI) chatbots to assist pharmacists providing MI advice.
Duncan Yorkston +2 more
wiley +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 MARSHALLESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and
core
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo +5 more
wiley +1 more source